Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomimetic, synthetic HDL nanostructures for lymphoma.

Literature DB >> 23345442

Biomimetic, synthetic HDL nanostructures for lymphoma.

Shuo Yang¹, Marina G Damiano, Heng Zhang, Sushant Tripathy, Andrea J Luthi, Jonathan S Rink, Andrey V Ugolkov, Amareshwar T K Singh, Sandeep S Dave, Leo I Gordon, C Shad Thaxton.

Abstract

New therapies that challenge existing paradigms are needed for the treatment of cancer. We report a nanoparticle-enabled therapeutic approach to B-cell lymphoma using synthetic high density lipoprotein nanoparticles (HDL-NPs). HDL-NPs are synthesized using a gold nanoparticle template to control conjugate size and ensure a spherical shape. Like natural HDLs, biomimetic HDL-NPs target scavenger receptor type B-1, a high-affinity HDL receptor expressed by lymphoma cells. Functionally, compared with natural HDL, the gold NP template enables differential manipulation of cellular cholesterol flux in lymphoma cells, promoting cellular cholesterol efflux and limiting cholesterol delivery. This combination of scavenger receptor type B-1 binding and relative cholesterol starvation selectively induces apoptosis. HDL-NP treatment of mice bearing B-cell lymphoma xenografts selectively inhibits B-cell lymphoma growth. As such, HDL-NPs are biofunctional therapeutic agents, whose mechanism of action is enabled by the presence of a synthetic nanotemplate. HDL-NPs are active in B-cell lymphomas and potentially, other malignancies or diseases of pathologic cholesterol accumulation.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23345442 PMCID： PMC3574906 DOI： 10.1073/pnas.1213657110

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

36 in total

Review 1. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology.

Authors: Marie-Christine Daniel; Didier Astruc
Journal: Chem Rev Date: 2004-01 Impact factor: 60.622

2. Comparative uptake of rat and human serum low-density and high-density lipoproteins by rat aortic smooth muscle cells in culture.

Authors: O Stein; Y Stein
Journal: Circ Res Date: 1975-03 Impact factor: 17.367

3. Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

Authors: M F Mulas; C Abete; D Pulisci; A Pani; B Massidda; S Dessì; A Mandas
Journal: Cell Prolif Date: 2011-06-06 Impact factor: 6.831

4. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity.

Authors: Miao Yu; Katherine A Romer; Thomas J F Nieland; Shangzhe Xu; Veronica Saenz-Vash; Marsha Penman; Ayce Yesilaltay; Steven A Carr; Monty Krieger
Journal: Proc Natl Acad Sci U S A Date: 2011-07-11 Impact factor: 11.205

Review 5. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders.

Authors: David Rhainds; Louise Brissette
Journal: Int J Biochem Cell Biol Date: 2004-01 Impact factor: 5.085

Review 6. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.

Authors: Attilio Rigotti; Helena E Miettinen; Monty Krieger
Journal: Endocr Rev Date: 2003-06 Impact factor: 19.871

7. Cholesterol-dependent infection of Burkitt's lymphoma cell lines by Epstein-Barr virus.

Authors: Rebecca B Katzman; Richard Longnecker
Journal: J Gen Virol Date: 2003-11 Impact factor: 3.891

8. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors: Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal: N Engl J Med Date: 2002-06-20 Impact factor: 91.245

9. Localization and regulation of SR-BI in membrane rafts of HepG2 cells.

Authors: David Rhainds; Philippe Bourgeois; Geneviève Bourret; Karine Huard; Louise Falstrault; Louise Brissette
Journal: J Cell Sci Date: 2004-07-01 Impact factor: 5.285

10. Uptake of a cholesterol-rich emulsion by breast cancer.

Authors: Silvia R Graziani; Fernando A F Igreja; Roberto Hegg; Claudio Meneghetti; Laura I Brandizzi; Renato Barboza; Rosângela F Amâncio; José A Pinotti; Raul C Maranhão
Journal: Gynecol Oncol Date: 2002-06 Impact factor: 5.482

56 in total

Review 1. Hybrid lipid-nanoparticle complexes for biomedical applications.

Authors: Kevin M Vargas; Young-Seok Shon
Journal: J Mater Chem B Date: 2019-01-03 Impact factor: 6.331

2. Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution.

Authors: Bhabatosh Banik; Ru Wen; Sean Marrache; Anil Kumar; Nagesh Kolishetti; Elizabeth W Howerth; Shanta Dhar
Journal: Nanoscale Date: 2017-12-21 Impact factor: 7.790

3. Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

Authors: Chitra Subramanian; Peter T White; Rui Kuai; Avinaash Kalidindi; Valerie P Castle; James J Moon; Barbara N Timmermann; Anna Schwendeman; Mark S Cohen
Journal: Surgery Date: 2018-05-09 Impact factor: 3.982

Biomimetic, synthetic HDL nanostructures for lymphoma.

Review 1. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology.

2. Comparative uptake of rat and human serum low-density and high-density lipoproteins by rat aortic smooth muscle cells in culture.

3. Cholesterol esters as growth regulators of lymphocytic leukaemia cells.

4. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity.

Review 5. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders.

Review 6. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.

7. Cholesterol-dependent infection of Burkitt's lymphoma cell lines by Epstein-Barr virus.

8. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

9. Localization and regulation of SR-BI in membrane rafts of HepG2 cells.

10. Uptake of a cholesterol-rich emulsion by breast cancer.

Review 1. Hybrid lipid-nanoparticle complexes for biomedical applications.

2. Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution.

3. Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

4. Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.

Review 5. Synthetic high-density lipoprotein-like nanoparticles for cancer therapy.

6. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.

Review 7. Update on current and potential nanoparticle cancer therapies.

8. Nanomedicines for Endothelial Disorders.

Review 9. High-density lipoprotein mimetics: promises and challenges.

Review 10. Lipoproteins and lipoprotein mimetics for imaging and drug delivery.